Terms: = Prostate cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Prognosis
341 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract] [Full Text] [Related]
3. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
[TBL] [Abstract] [Full Text] [Related]
4. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
5. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
6. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of risk factors for positive surgical margin after laparoscopic radical prostatectomy with and without neoadjuvant hormonal therapy.
Wang F; Zhang G; Tang Y; Wang Y; Li J; Xing N
Front Endocrinol (Lausanne); 2023; 14():1270594. PubMed ID: 37941905
[TBL] [Abstract] [Full Text] [Related]
8. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists.
Bonde TM; Garmo H; Stattin P; Nilsson P; Gunnlaugsson A; Swanberg D; Robinson D
Acta Oncol; 2023 Dec; 62(12):1815-1821. PubMed ID: 37850633
[TBL] [Abstract] [Full Text] [Related]
9. Primary signet ring cell carcinoma of prostate: A rare case report and review of literature.
Gupta M; Budhwar A; Prasad N; P Prasad SKS; Singh S
J Cancer Res Ther; 2023; 19(5):1075-1078. PubMed ID: 37787266
[TBL] [Abstract] [Full Text] [Related]
10. Nanoarray Enabled Size-Dependent Isolation and Proteomics Profiling of Small Extracellular Vesicle Subpopulations toward Accurate cancer Diagnosis and prognosis.
Wang S; He Y; Tian T; Lu J; Lu Y; Huang X; Zou Y; Zhang L; Fang X; Liu B
Anal Chem; 2023 Oct; 95(41):15276-15285. PubMed ID: 37782295
[TBL] [Abstract] [Full Text] [Related]
11. A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
Cameron JM; Sala A; Antoniou G; Brennan PM; Butler HJ; Conn JJA; Connal S; Curran T; Hegarty MG; McHardy RG; Orringer D; Palmer DS; Smith BR; Baker MJ
Br J Cancer; 2023 Nov; 129(10):1658-1666. PubMed ID: 37717120
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Survival in Patients with cancers: Surveillance, epidemiology and end results-based analysis.
Sakr RA; Nasr AA; Zineldin EI; Gouda MA
Sultan Qaboos Univ Med J; 2023 Aug; 23(3):344-350. PubMed ID: 37655083
[TBL] [Abstract] [Full Text] [Related]
13. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of holmium laser, bipolar and conventional monopolar transurethral resection of bladder tumour in primary non-muscle invasive bladder cancer.
Elmekawy S; Taha DE; Nabeeh HE; Ibrahim A; Zeid AE; Abdelbaky T
J Pak Med Assoc; 2023 Apr; 73(Suppl 4)(4):S251-S256. PubMed ID: 37482868
[TBL] [Abstract] [Full Text] [Related]
15. C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer.
Lorigo J; Tavares Silva E; Pedroso Lima J; Quaresma V; Pedrosa R; Figueiredo A
Arch Ital Urol Androl; 2023 Jul; 95(3):11242. PubMed ID: 37435750
[TBL] [Abstract] [Full Text] [Related]
16. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
17. High Expression of MRE11A Is Associated with Shorter Survival and a Higher Risk of Death in CRC Patients.
Azambuja DB; E Gloria HC; Montenegro GES; Kalil AN; Hoffmann JS; Leguisamo NM; Saffi J
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372450
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case-control study for a rare cancer entity.
Chen S; Song W; Zhang R; Jin Y; Lu Y; Lin L; Ye L; Li T; Wei Y
Sci Rep; 2023 Jun; 13(1):10317. PubMed ID: 37365217
[TBL] [Abstract] [Full Text] [Related]
19. Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel.
Modonutti D; Majdalany SE; Butaney M; Davis MJ; Corsi N; Sood A; Trinh QD; Cole AP; Rogers CG; Novara G; Abdollah F
Prostate; 2023 Sep; 83(13):1238-1246. PubMed ID: 37290911
[TBL] [Abstract] [Full Text] [Related]
20. Head-to-Head Comparison of
Exterkate L; Hermsen R; Küsters-Vandevelde HVN; Prette JF; Baas DJH; Somford DM; van Basten JA
Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
[TBL] [Abstract] [Full Text] [Related]
[Next]
